Active Recombinant Canine MS4A1 protein, His-tagged
Cat.No. : | MS4A1-3049C |
Product Overview : | Recombinant Canine MS4A1 protein(Met 1-Pro 297), fused with His tag, was expressed in HEK293. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Canine |
Tag : | His |
Form : | Supplied as 0.2 μm filtered solution in 20 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant. |
Bio-activity : | Immobilized Canine CD20 Full Length Protein, His Tag at 5 μg/mL (100 μL/well) can bind Anti-Dog CD20 Antibody, Rabbit IgG with a linear range of 5-78. |
Molecular Mass : | This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 35.2 kDa. The protein migrates as 25 kDa and 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation. The membrane scaffold protein (MSP1D1) has calculated MW of 24.7 kDa, and it migrates as 25 kDa under reducing (R) condition (SDS-PAGE).Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution. The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent. |
Protein length : | Met 1-Pro 297 |
Endotoxin : | Less than 1.0 EU per μg by the LAL method. |
Purity : | >80% as determined by SDS-PAGE. |
Storage : | For long term storage, the product should be stored at lyophilized state at-20°C or lower.Please avoid repeated freeze-thaw cycles. This product is stable after storage at:-20°C to-70°C for 12 months in lyophilized state;-70°C for 3 months under sterile conditions after reconstitution. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
Products Types
◆ Recombinant Protein | ||
MS4A1-432D | Recombinant Dog MS4A1 protein, His&Myc-tagged | +Inquiry |
Ms4a1-830M | Recombinant Mouse Ms4a1 Protein, MYC/DDK-tagged | +Inquiry |
MS4A1-23H | Recombinant Human MS4A1 Protein (T2-P297 end), N-8×His-Flag-TEV-tagged | +Inquiry |
MS4A1-09F | Recombinant Ferret MS4A1 protein(Glu213-Pro297), His-tagged | +Inquiry |
MS4A1-22H | Recombinant Human MS4A1 Protein (T2-P297 end), N-8×His-Flag-TEV-tagged | +Inquiry |
◆ Lysates | ||
MS4A1-1848FCL | Recombinant Ferret MS4A1 cell lysate | +Inquiry |
MS4A1-819CCL | Recombinant Cynomolgus MS4A1 cell lysate | +Inquiry |
MS4A1-1542HCL | Recombinant Human MS4A1 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewIts strong affinity allows for robust binding to target proteins, thereby enhancing the accuracy of analysis.
Surpassing expectations, it significantly amplifies the results of my research.
The operational guidelines for this reagent are readily comprehensible and accessible, facilitating seamless implementation of experiments, even for individuals lacking prior expertise.
Q&As (7)
Ask a questionMS4A1 expression is tightly regulated during different stages of B-cell development. It is absent in early B-cell progenitors and gradually increases during maturation. MS4A1 expression is upregulated upon B-cell activation and can be influenced by various cytokines and signaling pathways. This tightly controlled expression pattern ensures proper B-cell development, while aberrant regulation may contribute to B-cell disorders or malignancies.
MS4A1 expression levels have been explored as potential diagnostic or prognostic markers for certain B-cell disorders. Quantification of CD20 expression by immunohistochemistry or flow cytometry can aid in the diagnosis and classification of B-cell malignancies. Additionally, low CD20 expression levels have been associated with resistance to CD20-targeted therapies, serving as a prognostic indicator in B-cell lymphomas.
While CD20-targeted antibodies have revolutionized the treatment of B-cell malignancies, further therapeutic strategies are being explored. These include enhancing CD20 internalization, using antibody-drug conjugates, and developing novel targeted therapies based on the signaling pathways associated with MS4A1. Investigating these approaches may provide alternative treatments and improve outcomes for patients with B-cell disorders.
MS4A1 helps maintain immune tolerance by preventing the production of autoreactive B cells. It contributes to the elimination of self-reactive B cell clones through mechanisms such as antibody-dependent cellular cytotoxicity and antibody-mediated phagocytosis. MS4A1 dysregulation, however, can lead to the production of autoantibodies and the development of autoimmune diseases. Understanding the fine-tuned regulation of MS4A1's functions is essential for maintaining immune homeostasis and preventing autoimmunity.
MS4A1 interacts with multiple proteins, such as tetraspanins, Src-family kinases, and lipid rafts, which form a complex network involved in B-cell signaling. Upon ligand binding, MS4A1 activates intracellular signaling pathways, including PI3K/Akt and MAPK/ERK, which regulate B-cell survival, proliferation, and differentiation. Understanding these pathways and their crosstalk with MS4A1 can provide insights into B-cell activation and potential therapeutic targets.
The MS4A1 protein, also known as CD20, is a tetraspanin membrane protein found predominantly in B cells. It plays a crucial role in B-cell development, activation, and antibody production. Structurally, CD20 consists of four transmembrane domains and a large extracellular loop. Functionally, it regulates B-cell signaling by promoting calcium influx upon B-cell receptor activation, modulating cell cycle progression, and facilitating antibody-mediated cytotoxicity.
MS4A1 dysregulation has been implicated in B-cell malignancies, including non-Hodgkin lymphomas and leukemia. Increased expression or altered signaling of MS4A1 may promote survival and proliferation of malignant B cells. CD20-targeted therapies, such as monoclonal antibodies, have been successfully employed in treating B-cell malignancies, highlighting the significance of MS4A1 as a therapeutic target in these diseases.
Ask a Question for All MS4A1 Products
Required fields are marked with *
My Review for All MS4A1 Products
Required fields are marked with *
Inquiry Basket